Core Insights - Beihai Kangcheng Pharmaceutical Co., Ltd. has successfully included its innovative drug, Geronine®, in China's first "Commercial Insurance Innovative Drug Directory," effective from January 1, 2026 [1][3] - Geronine® is the first domestically developed enzyme replacement therapy for patients aged 12 and above with Type I and III Gaucher disease, marking a significant advancement in the treatment of rare diseases in China [3][4] Company Overview - Beihai Kangcheng is a leading global biopharmaceutical company focused on rare diseases, dedicated to the research, development, and commercialization of innovative therapies [1] - The company has established a strategic partnership with Baiyang Pharmaceutical, which invested in Beihai Kangcheng in August 2025, focusing on the commercialization of rare disease products [1][4] Market Context - In the 2025 National Medical Insurance negotiations, 121 products applied for the Commercial Insurance Innovative Drug Directory, with only 19 drugs from 18 innovative companies successfully included, highlighting the competitive landscape for innovative drugs in China [1] - The Commercial Insurance Innovative Drug Directory aims to support high-innovation drugs that are not yet included in the basic medical insurance catalog, providing broader access to effective treatments for patients [4] Future Prospects - The inclusion of Geronine® in the directory is expected to enhance the accessibility of this innovative domestic enzyme replacement therapy for Gaucher disease patients, reflecting the urgent medical needs in this area [3][4] - Baiyang Pharmaceutical is actively expanding its portfolio in the innovative drug sector, with investments in various therapeutic areas, indicating a commitment to advancing healthcare solutions in China [4]
百洋医药投资企业北海康成罕见病创新药戈芮宁成功入选首版“商保创新药目录”